Business Context and Reporting Period
This Form 8-K Current Report was filed by Propanc Biopharma, Inc. (formerly Propanc Health Group Corporation) on June 1, 2017, covering events occurring on May 26, 2017, and June 1, 2017. The Company is incorporated in Delaware with principal executive offices in Camberwell, Australia.
Key Financial Metrics and Debt
- Debt Issuance: Entered into a Securities Purchase Agreement with GS Capital Partners, LLC for an 8% convertible redeemable junior subordinated promissory note.
- Principal Amount: $160,000.
- Maturity Date: May 17, 2018.
- Interest Rate: 8% per annum; increases to 24% per annum (or highest rate permitted by law) upon an event of default.
- Conversion Terms: Convertible into common stock commencing November 17, 2017, at a price equal to 62% of the lowest closing bid price of the Common Stock for the ten trading days prior to conversion.
- Prepayment: Permitted with certain penalties within 180 days of issuance.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or overall liquidity positions.
Material Changes
- Corporate Name and Ticker: The Company changed its ticker symbol from PPCH to PPCB effective June 1, 2017, to reflect its name change from Propanc Health Group Corporation to Propanc Biopharma, Inc.
- Capital Structure: Creation of a new direct financial obligation via the $160,000 note, which is unregistered under Section 4(a)(2) of the Securities Act of 1933.
Outlook, Risks, and Contingencies
- Default Risks: Upon an event of default, principal and accrued interest become immediately due. The interest rate escalates to 24%, and penalty/liquidated damage provisions may be triggered.
- Dilution Risk: The conversion price mechanism (62% of the lowest closing bid) presents significant potential dilution to existing shareholders if the stock price declines prior to conversion.
- Management Commentary: The Company posted an investor fact sheet and presentation to its website on June 1, 2017, though the specific content of these documents is not detailed in the filing text.
Investor Verification Checklist
- Verify the current trading price of PPCB to assess the potential dilution impact of the 62% conversion discount.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and the Note (Exhibit 4.1) for specific default triggers and prepayment penalty calculations.
- Confirm the Company's cash position to ensure it can service the 8% interest and principal repayment by May 2018.
- Check for any subsequent filings regarding the utilization of the $160,000 proceeds.